A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT04647344 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV

Interventions

DRUG: AK104 plus Carboplatin and Pemetrexed
DRUG: AK104 plus Carboplatin and paclitaxel

Sponsor

Akeso